Free Trial

Silk Road Medical Q1 2023 Earnings Report

Silk Road Medical logo

Silk Road Medical EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.39
Beat/Miss
Missed by -$0.04
One Year Ago EPS
-$0.48

Silk Road Medical Revenue Results

Actual Revenue
$40.13 million
Expected Revenue
$40.69 million
Beat/Miss
Missed by -$560.00 thousand
YoY Revenue Growth
+43.20%

Silk Road Medical Announcement Details

Quarter
Q1 2023
Time
After Market Closes
“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Silk Road Medical Earnings Headlines

WARNING: “Buffett Indicator” flashing for first time in 50 years
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
See More Silk Road Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silk Road Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silk Road Medical and other key companies, straight to your email.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

View Silk Road Medical Profile

More Earnings Resources from MarketBeat